Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

thday. Children born prematurely as well as those with CLD or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract.

About Synagis

Synagis is the only MAb approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Since its licensure in 1998, Synagis has been administered to more than 1,000,000 infants in the U.S. and has become the standard of care for infants at high risk for RSV. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere during the winter months. Synagis is a humanized MAb given by an intramuscular injection once a month during the RSV season. Synagis was approved in 1998 by the FDA; in 1999, by the European Medicines Evaluation Agency; and in 2002, by the Japanese Ministry of Health, Labor and Welfare. In 2003, the FDA expanded the U.S. label for Synagis for use in young children with hemodynamically significant CHD at risk of RSV disease. To date, Synagis has been approved in 62 countries, including the United States. Synagis is indicated for the prevention of serious lower respiratory t
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... Mutations; Addresses Underlying Cause of,Genetic Disorders and Restores ... /PRNewswire/ -- New,preclinical data published online in the ... an investigational new drug,designed to bypass nonsense mutations, ... dystrophy (DMD). It is,estimated that approximately 13 percent ...
... NUTLEY, N.J., April 23, 2007 /PRNewswire/ --,An activity-based ... administered once every four weeks replaced thrice weekly,administration ... 802 nursing hours and more than $44,000 per ... prospective analysis of,anemia management in hemodialysis patients, were ...
Cached Medicine Technology:Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 2Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 3
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... and Distinguished Teaching Professor in the Department ... recently discussed facial fat compartments, fat grafting, and ... The Meeting," an annual conference held by the ... and intricacies of this underlying facial structure were ...
(Date:11/26/2014)... By Amy Norton ... -- While people have long believed their dogs understand what ... meaning and emotion of words in a human-like way. ... of human speech -- including the actual content and the ... team,s findings give a deeper insight into the canine brain, ...
(Date:11/26/2014)... News) -- More than half of Americans with dementia ... skills, a new study suggests. As reported ... million Americans over the age of 70 with dementia ... abilities," study author Dr. Vikas Kotagal, of the University ... a journal news release. The finding is important ...
(Date:11/26/2014)... 2014 The Deptford Center for ... a partnership designed to improve the quality of ... failure (CHF) patients in the South Jersey area. ... Cardiology team will help CHF patients manage their ... partnership pairs the Cardiac Recovery program at the ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules ... mesothelioma that looks and acts similar to asbestos-induced mesothelioma. ... the research. Click here to read it now. ... and Experimental Medicine in Hannover injected 500 lab rats ... rats eventually developed mesothelioma , how quickly it ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:Too Few Americans Undergo Dementia Screening 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
... ... introduced anti aging ingredients to its already popular product to make it the complete skin ... (PRWEB) March ... skin brightener available. , , ,Age spots, liver spots, brown patches, freckles, acne scars and ...
... ... to grow, unethical companies are beginning to produce imitation products to benefit from the success ... phony products before they become too large to control. , ... Milford, CT (PRWEB) March 16, 2010 -- They say imitation ...
... ... global medical device manufacturers are leveraging integrated, domain-specific Revenue Management to reclaim lost revenue ... ... , the leader in Revenue Management solutions for global Life Science organisations, and a ...
... ... and who are looking to better their health, too, can now turn to the GBG ... , ... -- Independent businessman Brad Aspin and leading health and wellness company GBG, provider of the ...
... NANJING , March 16 /PRNewswire-Asia/ -- ... ), a leading pharmaceutical company,specializing in the development, manufacturing, and ... unaudited,financial results for the quarter and the fiscal year ended ... Highlights, -- Total revenue was RMB539.4 million ...
... ,, WINDERMERE, Fla. , March 15 ... health care industry,s leader in transparent pharmacy benefits assessment, has ... neutrality reviews as the first quarter closes in 2010.  The ... (AWP) values by First DataBank (FDB) and Medispan may very ...
Cached Medicine News:Health News:Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 3Health News:Media Alert: Model N and International Medical Device Leader to Share Insights on Maximizing Sales Performance with Revenue Management 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 14Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 15Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 16Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 17Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 18Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 19Health News:ARMSRx Evaluation of AWP Neutrality 2Health News:ARMSRx Evaluation of AWP Neutrality 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: